Attendo AB (publ) (ATT.ST)
SEK 51.8
(1.77%)
SEK 51.8
(1.77%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 4.64 Billion SEK | 15.23% |
| 2022 | 13.91 Billion SEK | 14.76% |
| 2021 | 12.12 Billion SEK | 3.87% |
| 2020 | 11.67 Billion SEK | 3.02% |
| 2019 | 11.32 Billion SEK | 8.61% |
| 2018 | 10.43 Billion SEK | 2.16% |
| 2017 | 10.2 Billion SEK | 9.69% |
| 2016 | 9.3 Billion SEK | 3.8% |
| 2015 | 8.96 Billion SEK | 160.56% |
| 2014 | 3.44 Billion SEK | -53.56% |
| 2013 | 7.4 Billion SEK | 6.56% |
| 2012 | 6.95 Billion SEK | 8.71% |
| 2011 | 6.39 Billion SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.56 Billion SEK | 11.15% |
| 2024 Q3 | 4.36 Billion SEK | -4.4% |
| 2024 Q1 | 4.1 Billion SEK | -1.68% |
| 2023 Q2 | 4.06 Billion SEK | 6.47% |
| 2023 Q1 | 3.81 Billion SEK | 3.11% |
| 2023 Q3 | 3.96 Billion SEK | -2.36% |
| 2023 FY | 16.03 Billion SEK | 15.23% |
| 2023 Q4 | 4.17 Billion SEK | 5.27% |
| 2022 FY | 13.91 Billion SEK | 14.76% |
| 2022 Q4 | 3.7 Billion SEK | 8.98% |
| 2022 Q3 | 3.39 Billion SEK | -1.65% |
| 2022 Q2 | 3.45 Billion SEK | 2.98% |
| 2022 Q1 | 3.35 Billion SEK | 5.21% |
| 2021 Q1 | 2.9 Billion SEK | -1.69% |
| 2021 Q2 | 3.07 Billion SEK | 5.61% |
| 2021 Q3 | 2.95 Billion SEK | -3.81% |
| 2021 Q4 | 3.18 Billion SEK | 7.96% |
| 2021 FY | 12.12 Billion SEK | 3.87% |
| 2020 Q3 | 2.74 Billion SEK | -8.23% |
| 2020 Q4 | 2.95 Billion SEK | 7.8% |
| 2020 FY | 11.67 Billion SEK | 3.02% |
| 2020 Q1 | 2.97 Billion SEK | -1.23% |
| 2020 Q2 | 2.99 Billion SEK | 0.4% |
| 2019 Q1 | 2.65 Billion SEK | -4.05% |
| 2019 Q2 | 2.9 Billion SEK | 9.34% |
| 2019 Q3 | 2.75 Billion SEK | -5.2% |
| 2019 FY | 11.32 Billion SEK | 8.61% |
| 2019 Q4 | 3.01 Billion SEK | 9.52% |
| 2018 FY | 10.43 Billion SEK | 2.16% |
| 2018 Q4 | 2.76 Billion SEK | 8.89% |
| 2018 Q3 | 2.54 Billion SEK | -4.11% |
| 2018 Q2 | 2.65 Billion SEK | -11.6% |
| 2018 Q1 | 2.99 Billion SEK | 6.69% |
| 2017 Q2 | 2.54 Billion SEK | 5.64% |
| 2017 FY | 10.2 Billion SEK | 9.69% |
| 2017 Q3 | 2.43 Billion SEK | -4.43% |
| 2017 Q4 | 2.81 Billion SEK | 15.39% |
| 2017 Q1 | 2.41 Billion SEK | -1.23% |
| 2016 Q1 | 2.28 Billion SEK | -4.07% |
| 2016 FY | 9.3 Billion SEK | 3.8% |
| 2016 Q3 | 2.25 Billion SEK | -2.59% |
| 2016 Q2 | 2.31 Billion SEK | 1.31% |
| 2016 Q4 | 2.44 Billion SEK | 8.19% |
| 2015 FY | 8.96 Billion SEK | 160.56% |
| 2015 Q4 | 2.38 Billion SEK | 12.39% |
| 2015 Q1 | 2.21 Billion SEK | 184.43% |
| 2015 Q2 | 2.24 Billion SEK | 1.49% |
| 2015 Q3 | 2.12 Billion SEK | -5.52% |
| 2014 Q3 | 1.98 Billion SEK | 0.0% |
| 2014 FY | 3.44 Billion SEK | -53.56% |
| 2014 Q4 | -2.62 Billion SEK | -232.04% |
| 2013 FY | 7.4 Billion SEK | 6.56% |
| 2012 FY | 6.95 Billion SEK | 8.71% |
| 2011 FY | 6.39 Billion SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Ambea AB (publ) | 2.46 Billion SEK | -88.74% |
| Humana AB (publ) | 376 Million SEK | -1134.84% |
| ProstaLund AB (publ) | 31.95 Million SEK | -14427.989% |